[1] SHEN C, GE J. Epidemic of cardiovascular disease in China[J]. Circulation, 2018, 138(4): 342-344.
[2] AMBROSY A P, FONAROW G C, BUTLER J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12): 1123-1133.
[3] MENTZ R J, O′CONNOR C M. Pathophysiology and clinical evaluation of acute heart failure[J]. Nat Rev Cardio, 2016, 13(1): 28-35.
[4] NORMAND C, KAYE D M, POVSIC T J, et al. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology[J]. Lancet, 2019, 393(10175): 1045-1055.
[5] SUN J, ZHANG K, XIONG W J, et al. Clinical effects of a standardized Chinese herbal remedy, Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis[J]. BMC Complement Altern Med, 2016, 16: 201.
[6] 中华医学会心血管病学分会心力衰竭学组, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[7] AHLBOM M, HAGERMAN I, STAHLBERG M, et al. Increases in cardiac output and oxygen consumption during enhanced external counterpulsation[J]. Heart Lung Circ, 2016, 25(11): 1133-1136.
[8] DI PALO K E, BARONE N J. Hypertension and heart failure: prevention, targets, and treatment[J]. Heart fail Clin, 2020, 16(1): 99-106.
[9] ZHANG H, LI S, ZHOU Q, et al. Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy through downregulation of MiR-199a-5p[J]. Cell Physiol Biochem, 2016, 38(5): 1743-1751.
[10] LIN S, WU X, TAO L, et al. The metabolic effects of traditional Chinese medication Qiliqiangxin on H9C2 cardiomyocytes[J]. Cell Physiol Biochem, 2015, 37(6): 2246-2256.
[11] ZHANG J, HUANG M, SHEN S, et al. Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice[J]. Am J Transl Res, 2017, 9(12): 5585-5593.
[12] LI X, ZHANG J, HUANG J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
[13] RAZA A, STEINBERG K, TARTAGLIA J, et al. Enhanced external counterpulsation therapy: past, present, and future[J]. Cardiol Rev, 2017, 25(2): 59-67.
[14] XIONG Y, REN Y F, XU J, et al. Enhanced external counterpulsation inhibits endothelial apoptosis via modulation of BIRC2 and Apaf-1 genes in porcine hypercholesterolemia[J]. Intern J Cardiol, 2014, 171(2): 161-168.
[15] BECK D T, MARTIN J S, CASEY D P, et al. Enhanced external counterpulsation improves endothelial function and exercise capacity in patients with ischaemic left ventricular dysfunction[J]. Clin Exp Pharmacol Physiol, 2014, 41(9): 628-636.
[16] KIERNAN T J, BOILSON B A, TESMER L, et al. Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets[J]. Intern J Cardiology, 2011, 153(2): 202-206.
[17] 刘娟, 丁清清, 周白瑜, 等. 中国老年人肌少症诊疗专家共识(2021)[J]. 中华老年医学杂志, 2021, 40(8):943-952. |
